Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple myeloma | D009101 | — | C90.0 | — | 1 | 2 | — | — | 2 |
Plasma cell neoplasms | D054219 | — | — | — | 1 | 2 | — | — | 2 |
Recurrence | D012008 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 2 | 2 | — | — | — | 3 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 1 | — | — | — | 2 |
Drug common name | Tanespimycin |
INN | tanespimycin |
Description | Tanespimycin (17-N-allylamino-17-demethoxygeldanamycin, 17-AAG) is a derivative of the antibiotic geldanamycin that is being studied in the treatment of cancer, specifically in younger patients with certain types of leukemia or solid tumors, especially kidney tumors.
|
Classification | Small molecule |
Drug class | antibiotics (Streptomyces strain) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)NC(=CC1=O)C2=O |
PDB | — |
CAS-ID | 75747-14-7 |
RxCUI | — |
ChEMBL ID | CHEMBL109480 |
ChEBI ID | 64153 |
PubChem CID | 6440175 |
DrugBank | — |
UNII ID | 4GY0AVT3L4 (ChemIDplus, GSRS) |